Global Economic Times

Encell Signs 8 Billion KRW CDMO Contract with Cerebrain... Collaboration on Gene Stem Cell Therapy Production: Global Economic Times Reporter / Updated : 2025-03-04 15:05:34

Encell (456070), a specialized company in advanced biopharmaceutical contract development and manufacturing (CDMO) and new drug development, announced on the 4th that it has signed a CDMO contract worth approximately 8 billion KRW with biopharmaceutical development company Cerebrain. The contract period is until March 3, 2026, and specific contract details were not disclosed due to a confidentiality agreement between the two companies.

Encell, a Leading Domestic CGT CDMO Company, Provides One-Stop Service Based on GMP Facilities
Encell is the leading company in the domestic cell and gene therapy (CGT) CDMO field in terms of sales and market share. It has global-level Good Manufacturing Practice (GMP) licensed facilities capable of simultaneously producing cells and viruses, and provides optimal CDMO solutions to customers through one-stop service and differentiated production quality management system.

Cerebrain Develops Gene Stem Cell Therapy for Brain Diseases... Possesses Innovative Platform Technology
Cerebrain is developing gene stem cell therapies that load functional genes into stem cells for brain diseases such as brain tumors and strokes. It possesses innovative platform technologies such as gene introduction technology and analysis technology necessary for high-efficiency, high-purity therapeutic development. Previously, Cerebrain successfully completed researcher-initiated clinical trials on patients with recurrent glioblastoma at CHA Hospital with gene stem cell therapy produced under contract in 2018.

Encell-Cerebrain Collaborate on Production of Gene-Loaded Stem Cell Therapy
Through this contract, Encell plans to support the production of Cerebrain's gene-introduced master cell bank (MCB) into gene-loaded stem cell therapy based on its GMP platform technology, so that it can be applied to advanced regenerative clinical research and treatment.

Jang Jong-wook, CEO of Encell, said, "Through this contract, we will do our best with our customers to produce Cerebrain's gene-introduced master cell bank (MCB) into gene-loaded stem cell therapy based on Encell's core CDMO technology, the GMP platform technology, so that it can be applied to advanced regenerative clinical research and treatment."

Seo Hae-young, CEO of Cerebrain, said, "Cerebrain has high confidence in Encell's gene cell therapy-specialized manufacturing process and excellent quality control capabilities, which led to this contract." He added, "We will strive to prove the innovative treatment potential by entering late-stage clinical trials both domestically and internationally with the treatment produced through this contract."